Kaul S, Gosmanova EO, Castriota F, Hitchens A, Candrilli S, Parikh R, Esterberg E, Ayodele O. Recent trends in hypoparathyroidism-related inpatient and emergency department admissions and costs in the United States. J Endocr Soc. 2023 Apr 18;7(5):bvad050. doi: 10.1210/jendso/bvad050.
Ervin C, Joish VN, Castro C, DiBenedetti D, Evans E, Carroll A, Lapuerta P. Elevating the patient voice in type 1 diabetes clinical trials: a comparison of in-depth exit interviews and diabetes-specific questionnaires. Poster presented at the 2020 Endocrine Society Conference (ENDO2020) (Conference cancelled); March 2020. San Francisco, CA. [abstract] J Endocr Soc. 2020 May 8; 4(Suppl 1):MON-630. doi: 10.1210/jendso/bvaa046.1290
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Miron A, Schildkraut JM, Rimer BK, Winer EP, Sugg Skinner C, Futreal PA, Culler D, Calingaert B, Clark S, Kelly Marcom P, Iglehart JD. Testing for hereditary breast and ovarian cancer in the Southeastern United States. Ann Surg. 2000 May;231(5):624-34.
Clarkson T, Anthony MS, Hughes C. Estrogenic soybean isoflavones and chronic disease: risks and benefits. Trends Endocrinol Metab. 1995 Jan;6(1):11-6.